From: cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment
Cancer type | Effects of cAMP signaling | References |
---|---|---|
Leukemia | cAMP promotes leukemia progression | [91] |
cAMP inhibits anthracycline- and DNA-damage-induced apoptosis | [92] | |
cAMP-EPAC promotes ribosome-targeting therapy resistance in AML | [93] | |
cAMP sensitizes T-ALL to dexamethasone | [94] | |
cAMP-PKA sensitizes AML to GSKJ4 | [95] | |
Diffuse large B cell lymphoma | cAMP inhibits tumor cell survival and drug resistance | [96] |
Lung cancer | cAMP-PKA promotes cancer cell survival and EGFR inhibitor resistance | |
CREB1 enhances cisplatin sensitivity in lung cancer cells | [99] | |
Gastric cancer | cAMP promotes gastric carcinogenesis through activation of CREB, EPAC and DARPP-32 | |
Liver cancer | PKA activation drives fibrolamellar liver carcinoma | |
GNAS mutation promotes liver carcinogenesis via cAMP/JAK/STAT3 signaling | [107] | |
CREB promotes HCC metastasis and drug resistance | ||
cAMP/PKA mediates the tumor-suppression effects of Ex-4 | [111] | |
PDE4 inhibition suppresses HCC cell proliferation and survival | ||
Colorectal cancer | GPR43 deficiency promotes colon carcinogenesis by upregulated cAMP/PKA signaling | [114] |
Norepinephrine promotes colon cancer cell growth and invasion by inducing CREB phosphorylation | [115] | |
Breast cancer | PKA phosphorylates ERα and promotes tamoxifen resistance | [116] |
cAMP/PKA promotes chemotherapeutic resistance in inflammatory breast carcinoma | [117] | |
PAQR8 downregulates cAMP levels and promotes drug resistance | [118] | |
PKA upregulates PTEN and p53 and inhibits cell growth | ||
PKA enhances doxorubicin sensitivity in TNBC | [121] | |
cAMP/PKA inhibits NF-κB and breast cancer stemness | [122] | |
Ovarian cancer | cAMP inhibits p53 and DNA-damage-induces apoptosis in BRCA1-deficient ovarian cancer | [123] |
cAMP inhibits JNK activity and apoptosis | [124] | |
Melanoma | cAMP-EPAC inhibits PUMA expression and apoptosis | [62] |
cAMP stimulates the growth of primary melanoma but not the metastatic melanoma | ||
cAMP-PKA promotes vemurafenib resistance | [128] | |
Prostate cancer | PKA promotes AR activation, and abiraterone, enzalutamide, castration resistance | |
cAMP-PKA promotes metastasis | [133] | |
Medulloblastoma | cAMP-PKA suppresses medulloblastoma by phosphorylating and inactivating Gli | [134] |
Basal cell carcinoma of the skin | cAMP-PKA abolishes oncogenic Sonic hedgehog signaling and suppresses tumor growth | [135] |